Astrana Health (NASDAQ:ASTH) Issues Earnings Results

Astrana Health (NASDAQ:ASTH) issued its earnings results on Thursday. The company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.29 by $0.45, FiscalAI reports. The firm had revenue of $965.10 million during the quarter, compared to analyst estimates of $949.21 million. Astrana Health had a net margin of 0.86% and a return on equity of 9.31%. The company’s quarterly revenue was up 55.6% on a year-over-year basis. During the same quarter last year, the business earned $0.42 earnings per share.

Here are the key takeaways from Astrana Health’s conference call:

• Astrana reported a strong Q1 — $965.1M revenue (+56% YoY), adjusted EBITDA of $66.3M (+82% YoY), adjusted EPS of $0.74, free cash flow of $64.1M, and accelerated deleveraging to ~2.3x pro forma with a target of ?2.0x by year-end.
• Management highlighted its AI-enabled, payer-agnostic operating system, saying embedded AI agents are already improving outcomes and operations (24% higher gap-closure, 30% higher annual wellness completion, and much faster claims payment) and that benefits should compound over time.
• The business now serves ~1.55M members in value-based arrangements, with ~80% of Care Partners revenue and ~40% of owned membership in full-risk contracts; new full-risk cohorts are tracking to underwriting but Medicaid and Exchange enrollment trends were mixed.
• Prospect integration is on track — gross provider retention >99%, synergies tracking toward the high end of the $12–15M annual target, and Prospect is performing ahead toward ~$80M annualized adjusted EBITDA.
• The company reaffirmed 2026 guidance (revenue $3.8–4.1B, adjusted EBITDA $250–280M, FCF $105–132.5M), gave Q2 targets, and cited the 2027 Medicare Advantage rate notice and its encounter-based approach as structural regulatory tailwinds.

Astrana Health Price Performance

Shares of ASTH stock traded up $3.22 during trading hours on Friday, reaching $39.30. The stock had a trading volume of 929,945 shares, compared to its average volume of 474,463. The stock’s fifty day simple moving average is $27.38 and its 200 day simple moving average is $25.67. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.25. Astrana Health has a 12 month low of $18.08 and a 12 month high of $39.90. The firm has a market capitalization of $2.19 billion, a PE ratio of 64.43 and a beta of 0.98.

Key Headlines Impacting Astrana Health

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Astrana Health beat first-quarter sales expectations, reporting revenue of $965.1 million versus the $949.2 million consensus, while EPS came in at $0.74, well above the $0.29 estimate. Revenue also rose 55.6% year over year, signaling strong operating momentum. Article title
• Positive Sentiment: The company’s full-year 2026 revenue guidance of $3.8 billion to $4.1 billion was issued near Wall Street expectations, which can support confidence that growth remains intact. Article title
• Positive Sentiment: Needham & Company raised its price target on ASTH to $41 from $30 and kept a buy rating, while BTIG Research lifted its target to $50 from $40 and also reiterated a buy rating. Those moves suggest analysts see more upside after the earnings beat.
• Neutral Sentiment: Investors are also digesting the earnings call transcript and presentation, which may provide additional detail on margins, guidance, and the company’s growth strategy.

Hedge Funds Weigh In On Astrana Health

A number of large investors have recently modified their holdings of ASTH. Tower Research Capital LLC TRC boosted its position in shares of Astrana Health by 323.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after acquiring an additional 3,517 shares during the period. State of Wyoming bought a new position in shares of Astrana Health in the second quarter valued at approximately $132,000. Los Angeles Capital Management LLC bought a new position in shares of Astrana Health in the fourth quarter valued at approximately $228,000. WINTON GROUP Ltd bought a new position in shares of Astrana Health in the second quarter valued at approximately $233,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Astrana Health in the second quarter valued at approximately $277,000. 52.77% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ASTH has been the subject of a number of research reports. BTIG Research increased their target price on shares of Astrana Health from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday. Truist Financial increased their target price on shares of Astrana Health from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Zacks Research upgraded shares of Astrana Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 11th. Weiss Ratings upgraded shares of Astrana Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Finally, Robert W. Baird set a $45.00 target price on shares of Astrana Health in a research report on Friday. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.86.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.